BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 25099258)

  • 1. Increased platelet expression of glycoprotein IIIa following aspirin treatment in aspirin-resistant but not aspirin-sensitive subjects.
    Floyd CN; Goodman T; Becker S; Chen N; Mustafa A; Schofield E; Campbell J; Ward M; Sharma P; Ferro A
    Br J Clin Pharmacol; 2014 Aug; 78(2):320-8. PubMed ID: 25099258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study.
    Gurbel PA; Bliden KP; DiChiara J; Newcomer J; Weng W; Neerchal NK; Gesheff T; Chaganti SK; Etherington A; Tantry US
    Circulation; 2007 Jun; 115(25):3156-64. PubMed ID: 17562955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison between urinary 11-dehydrothromboxane B2 detection and platelet Light Transmission Aggregometry (LTA) assays for evaluating aspirin response in elderly patients with coronary artery disease.
    Liu T; Zhang J; Chen X; Feng X; Fu SW; McCaffrey TA; Liu M
    Gene; 2015 Oct; 571(1):23-7. PubMed ID: 26095809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced blood platelet sensitivity to aspirin in coronary artery disease: are dyslipidaemia and inflammatory states possible factors predisposing to sub-optimal platelet response to aspirin?
    Markuszewski L; Rosiak M; Golanski J; Rysz J; Spychalska M; Watala C
    Basic Clin Pharmacol Toxicol; 2006 May; 98(5):503-9. PubMed ID: 16635110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of platelet glycoprotein IIIa polymorphism in the high prevalence of in vitro aspirin resistance in patients with intracoronary stent restenosis.
    Pamukcu B; Oflaz H; Nisanci Y
    Am Heart J; 2005 Apr; 149(4):675-80. PubMed ID: 15990752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased platelet sensitivity among individuals with aspirin resistance - platelet aggregation to submaximal concentration of arachidonic acid predicts response to antiplatelet therapy.
    Guthikonda S; Mangalpally K; Vaduganathan M; Patel R; Delao T; Bergeron AL; Dong JF; Lev EI; Kleiman NS
    Thromb Haemost; 2008 Jul; 100(1):83-9. PubMed ID: 18612542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continued thromboxane A2 formation despite administration of a platelet glycoprotein IIb/IIIa antagonist in patients undergoing coronary angioplasty.
    Byrne A; Moran N; Maher M; Walsh N; Crean P; Fitzgerald DJ
    Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):3224-9. PubMed ID: 9409315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Residual platelet reactivity in low-dose aspirin-treated patients with class 1 obesity.
    Lee S; Eichelberger B; Kopp CW; Panzer S; Gremmel T
    Vascul Pharmacol; 2021 Feb; 136():106819. PubMed ID: 33207279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arachidonic acid-stimulated platelet tests: Identification of patients less sensitive to aspirin treatment.
    Temperilli F; Rina A; Massimi I; Montemari AL; Guarino ML; Zicari A; Pulcinelli FM
    Platelets; 2015; 26(8):783-7. PubMed ID: 25734355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease.
    Henry P; Vermillet A; Boval B; Guyetand C; Petroni T; Dillinger JG; Sideris G; Bal dit Sollier C; Drouet L
    Thromb Haemost; 2011 Feb; 105(2):336-44. PubMed ID: 21136023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening for aspirin resistance in stable coronary artery patients by three different tests.
    Chakroun T; Addad F; Abderazek F; Ben-Farhat M; Hamdi S; Gamra H; Hassine M; Ben-Hamda K; Samama MM; Elalamy I
    Thromb Res; 2007; 121(3):413-8. PubMed ID: 17553552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Homocysteine is a novel risk factor for suboptimal response of blood platelets to acetylsalicylic acid in coronary artery disease: a randomized multicenter study.
    Karolczak K; Kamysz W; Karafova A; Drzewoski J; Watala C
    Pharmacol Res; 2013 Aug; 74():7-22. PubMed ID: 23665469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of VerifyNowR with PlateletMappingR--detected aspirin resistance and correlation with urinary thromboxane.
    Carroll RC; Craft RM; Snider CC; Aligeti VR; Wortham DC
    Anesth Analg; 2013 Feb; 116(2):282-6. PubMed ID: 23302970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to aspirin in healthy individuals. Cross-comparison of light transmission aggregometry, VerifyNow system, platelet count drop, thromboelastography (TEG) and urinary 11-dehydrothromboxane B(2).
    Blais N; Pharand C; Lordkipanidzé M; Sia YK; Merhi Y; Diodati JG
    Thromb Haemost; 2009 Aug; 102(2):404-11. PubMed ID: 19652893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post interventional cardiology urinary thromboxane correlates with PlateletMapping detected aspirin resistance.
    Carroll RC; Worthington RE; Craft RM; Snider CC; Dakin PA; Wortham DC; Scott J; Jarrett A
    Thromb Res; 2010 Apr; 125(4):e118-22. PubMed ID: 19962724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The lack of aspirin resistance in patients with coronary artery disease.
    Homoródi N; Kovács EG; Leé S; Katona É; Shemirani AH; Haramura G; Balogh L; Bereczky Z; Szőke G; Péterfy H; Kiss RG; Édes I; Muszbek L
    J Transl Med; 2016 Mar; 14():74. PubMed ID: 26980433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet function recovery after cessation of aspirin: preliminary study of volunteers and surgical patients.
    Zisman E; Erport A; Kohanovsky E; Ballagulah M; Cassel A; Quitt M; Pizov R
    Eur J Anaesthesiol; 2010 Jul; 27(7):617-23. PubMed ID: 20035230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aspirin resistance in off-pump coronary artery bypass grafting.
    Wang Z; Gao F; Men J; Ren J; Modi P; Wei M
    Eur J Cardiothorac Surg; 2012 Jan; 41(1):108-12. PubMed ID: 21636287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aspirin resistance in Indian patients with coronary artery disease and cardiovascular events.
    Thomson VS; John B; George P; Joseph G; Jose J
    J Postgrad Med; 2009; 55(4):252-6. PubMed ID: 20083870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose- and time-dependent antiplatelet effects of aspirin.
    Perneby C; Wallén NH; Rooney C; Fitzgerald D; Hjemdahl P
    Thromb Haemost; 2006 Apr; 95(4):652-8. PubMed ID: 16601836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.